B7-H4 (human) (rec.)
435 CHF CHF 435.00
CHI-HF-200B7H4-C05050 µgCHF 435.00
|Synonyms||V-set Domain-containing T Cell Activation Inhibitor 1; VTCN1; B7h.5; Immune Costimulatory Protein B7-H4; T Cell Costimulatory Molecule B7x; Protein B7S1|
|Source/Host||HEK 293 cells|
|Sequence||The extracellular domain of human B7-H4 (aa 29-258).|
|Endotoxin Content||<0.01EU/μg protein (LAL test; Lonza).|
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Other Product Data||NCBI reference NP_078902.2: B7-H4 (human)|
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
B7-H4 is a B7 family member that negatively regulates T cell immunity by inhibiting of T cell proliferation, cytokine production, and cell cycle progression. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-cells (CTLs). In vivo, blockade of endogenous B7-H4 by specific monoclonal antibody promotes T cell responses. B7-H4 ia an important negative regulator of innate immunity through growth inhibition of neutrophils. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance.